4,440 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Sax Wealth Advisors LLC

Sax Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 4,440 shares of the company's stock, valued at approximately $382,000.

Several other large investors have also made changes to their positions in the company. Massachusetts Financial Services Co. MA grew its holdings in Novo Nordisk A/S by 2.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 77,494 shares of the company's stock worth $11,061,000 after acquiring an additional 1,860 shares during the period. Hsbc Holdings PLC boosted its position in shares of Novo Nordisk A/S by 19.4% in the 2nd quarter. Hsbc Holdings PLC now owns 54,804 shares of the company's stock worth $7,852,000 after purchasing an additional 8,922 shares during the last quarter. Brighton Jones LLC grew its position in shares of Novo Nordisk A/S by 62.9% during the 2nd quarter. Brighton Jones LLC now owns 14,570 shares of the company's stock worth $2,080,000 after buying an additional 5,625 shares during the period. Ieq Capital LLC raised its position in shares of Novo Nordisk A/S by 0.4% in the 2nd quarter. Ieq Capital LLC now owns 34,404 shares of the company's stock valued at $4,911,000 after acquiring an additional 128 shares during the period. Finally, Benjamin Edwards Inc. boosted its stake in Novo Nordisk A/S by 2.6% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company's stock worth $493,000 after acquiring an additional 87 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NVO. BNP Paribas upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. StockNews.com cut Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $140.20.

Novo Nordisk A/S Stock Down 5.2 %

Shares of Novo Nordisk A/S stock traded down $4.33 during trading on Friday, reaching $78.74. The stock had a trading volume of 21,239,835 shares, compared to its average volume of 8,206,201. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $353.33 billion, a price-to-earnings ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. The stock has a fifty day moving average price of $97.76 and a two-hundred day moving average price of $117.05. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.